# Xeris Biopharma Holdings, Inc.: Form 8-K, filed Sep 29, 2023

- Company: [Xeris Biopharma Holdings, Inc.](/companies/xers.md) (CIK 1867096)
- Form: 8-K
- Filed: 2023-09-29
- Accepted by EDGAR: Sep 29, 2023, 16:55 ET
- Period: 2023-09-29
- Accession: 0001867096-23-000125
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1867096/000186709623000125/xers-20230929.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1867096/000186709623000125/

## Items reported

- Item 1.01: Entry into a material agreement
- Item 2.03: New direct financial obligation
- Item 3.02: Unregistered sale of equity
- Item 9.01: Financial statements and exhibits

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1867096/000186709623000125/xers-20230929.htm

Filed Sep 29, 2023.
Source: SEC EDGAR, the filing index for accession 0001867096-23-000125. Last ingested by Listed: Nov 6, 2026, 17:33 ET. No prices; not investment advice.